Baracitinib news tops AAD Annual Meeting coverage

Healio was on site at this year’s American Academy of Dermatology Annual Meeting, covering a range of important dermatology news, including updates to atopic dermatitis, psoriasis and hair disorders.

Here are Healio’s top five most read or most watched AAD meeting updates and videos from 2022:

VIDEO: Long-term hair growth shown with baricitinib in alopecia areata

In this video, Brett A. King, MD, PhD, associate professor of dermatology at Yale School of Medicine, discusses the 52-week pooled analysis of two double-blind, placebo-controlled phase three trials he presented during the meeting’s late-breakers news session. Watch here.

Long-term ruxolitinib cream improves facial, body repigmentation

David Rosmarin, MD, clinical investigator and vice-chair for research and education at Tufts Medical Center, presented data from two identical phase 3 studies, TRuE-V1 and TRuE-V2, which each included more than 300 vitiligo patients. Read more.

Roflumilast efficacious in reducing seborrheic dermatitis itch

This phase 2 , parallel-group, double-blind, vehicle-controlled trial enrolled 226 adult seborrheic dermatitis patients who were randomly assigned to receive roflumilast foam 0.3% (Arcutis) or vehicle foam for 8 weeks. Read more.

Trifarotene plus doxycycline efficacious in severe acne treatment

A rapid improvement in severe acne was observed in patients treated with 12 weeks of trifarotene and doxycycline. Read more.

VIDEO: Galderma launches Twyneo cream for acne

In this video, Hilary Baldwin, MD, medical director of the Acne Research Center in Brooklyn, New York, discusses the science behind Twyneo cream. Watch here.